Loading...
19 ursodeoxycholic acid COVID-19 controlled studies
20% improvement, RR
0.80
[0.62-1.02]
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
Yu
39%
0.61 [0.38-0.99]
no recov.
65 (n)
50 (n)
Improvement, RR [CI]
Treatment
Control
Brevini (PSM)
94%
0.06 [0.00-2.37]
death
0/31
14/155
Brevini (PSM)
67%
0.33 [0.05-2.43]
ventilation
1/31
15/155
Brevini (PSM)
75%
0.25 [0.03-1.79]
ICU
1/31
20/155
Brevini (PSM)
40%
0.60 [0.37-0.99]
hosp.
11/31
91/155
John (PSM)
42%
0.58 [0.22-1.54]
death
1,607 (n)
1,607 (n)
John (PSM)
54%
0.46 [0.23-0.93]
severe case
1,607 (n)
1,607 (n)
John (PSM)
55%
0.45 [0.27-0.75]
m/s case
1,607 (n)
1,607 (n)
John (PSM)
50%
0.50 [0.36-0.69]
symp. case
1,607 (n)
1,607 (n)
John (PSM)
48%
0.52 [0.39-0.70]
cases
1,607 (n)
1,607 (n)
Li
40%
0.60 [0.15-2.48]
hosp.
3/225
5/225
Li
29%
0.71 [0.65-0.79]
hosp. time
225 (n)
225 (n)
Li
80%
0.20 [0.02-1.70]
severe case
1/225
5/225
Li
80%
0.20 [0.10-0.38]
m/s case
10/225
50/225
Li (PSM)
11%
0.89 [0.77-0.97]
cases
192/225
212/225
Yu
38%
0.62 [0.38-1.01]
no recov.
62 (n)
45 (n)
Liu
-2%
1.02 [0.83-1.25]
cases
95/146
51/80
Liu
-4%
1.04 [0.90-1.20]
cases
118/146
62/80
Okushin (PSM)
17%
0.83 [0.40-1.74]
symp. case
10/47
12/47
Okushin (PSM)
0%
1.00 [0.57-1.76]
cases
16/47
16/47
Okushin (PSM)
0%
1.00 [0.46-2.18]
symp. case
10/47
10/47
Okushin (PSM)
-7%
1.07 [0.60-1.90]
cases
16/47
15/47
Ojeda‐Fernández
-7%
1.07 [0.79-1.44]
death
54/219
259/1,141
Ojeda‐Fernández
4%
0.96 [0.25-3.65]
ICU
3/219
15/1,141
Ojeda‐Fernández
-6%
1.06 [0.83-1.36]
hosp.
77/219
393/1,141
Ojeda‐Fernández
3%
0.97 [0.81-1.16]
cases
n/a
n/a
Ojeda‐Fernández
-1%
1.01 [0.81-1.27]
cases
83/1,687
399/7,930
Ojeda‐Fernández
9%
0.91 [0.66-1.19]
cases
43/1,125
273/6,731
Marrone
-7%
1.07 [0.69-1.64]
death
26/108
118/521
Ming
13%
0.87 [0.77-0.98]
cases
185/3,804
297/5,060
high vs. low
Gao
12%
0.88 [0.75-0.99]
cases
114/163
183/230
Costello
24%
0.76 [0.53-1.08]
death
7,225 (n)
4,080 (n)
Costello
19%
0.81 [0.68-0.96]
hosp.
7,225 (n)
4,080 (n)
Costello
21%
0.79 [0.67-0.93]
death/hosp.
7,225 (n)
4,080 (n)
Corpechot
-54%
1.54 [0.44-5.40]
death
3/1,322
13/8,825
Corpechot
19%
0.81 [0.29-2.28]
ICU
4/1,322
33/8,825
Corpechot
40%
0.60 [0.29-1.24]
hosp.
1,322 (n)
8,825 (n)
Corpechot
52%
0.48 [0.20-1.19]
hosp.
6/1,322
80/8,825
Corpechot
7%
0.93 [0.26-3.29]
hosp.
case control
Cui (PSM)
48%
0.52 [0.31-0.89]
no recov.
13/64
51/131
Cui (PSM)
83%
0.17 [0.06-0.49]
cases
78 (n)
137 (n)
Zheng
62%
0.38 [0.16-0.91]
death
42 (n)
125 (n)
Li (PSM)
21%
0.79 [0.69-0.90]
symp. case
93/128
59/64
Li (PSM)
19%
0.81 [0.71-0.91]
cases
95/128
59/64
Li
18%
0.82 [0.68-0.99]
progression
93 (n)
59 (n)
Li
18%
0.82 [0.68-0.98]
progression
63/93
49/59
Li
26%
0.74 [0.60-0.92]
progression
55/93
47/59
Li
57%
0.43 [0.31-0.59]
progression
31/93
46/59
Li
-5%
1.05 [0.73-1.51]
progression
43/93
26/59
Li
18%
0.82 [0.56-1.20]
progression
35/93
27/59
Li
31%
0.69 [0.47-1.02]
progression
35/93
32/59
Li
-34%
1.34 [0.83-2.16]
progression
36/93
17/59
Li
-13%
1.13 [0.64-2.00]
progression
25/93
14/59
Li
10%
0.90 [0.46-1.74]
progression
17/93
12/59
Li
-11%
1.11 [0.50-2.48]
progression
14/93
8/59
Lee
57%
0.43 [0.12-1.52]
severe case
2,934 (n)
2,934 (n)
Lee (PSM)
79%
0.21 [0.09-0.46]
severe case
414 (n)
414 (n)
Lee (PSM)
23%
0.77 [0.62-0.95]
severe case
2,934 (n)
2,934 (n)
Lee
15%
0.85 [0.67-1.09]
cases
population-based cohort
Lee (PSM)
29%
0.71 [0.52-0.98]
cases
20,296 (n)
20,296 (n)
Lee (PSM)
7%
0.93 [0.90-0.96]
cases
population-based cohort
Moon (PSM)
33%
0.67 [0.46-0.98]
severe case
case control
Moon (PSM)
20%
0.80 [0.76-0.85]
cases
case control
Sakamaki
-79%
1.79 [1.69-1.89]
severe case
population-based cohort
Ursodeoxycholic acid COVID-19 outcomes
c19 early .org
December 2024
Favors UDCA
Favors control
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers.
Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit